The search for a series of drugs with high efficacy and low toxicities is a common dream of clinicians, patients with malignant hematological diseases and their relatives and friends. In recent years, the emergence of gene-targeted therapeutic drugs represented by imatinib mesylate (Gleeve, Gleeve), rituximab (Meroval) and anti-CD33 monoclonal antibody (Merotag, Mylotarg) has brought a new dawn to the treatment of hematologic diseases, making some patients with malignant or refractory hematologic diseases hopefully exempt from chemotherapy, hormones and immunosuppressive drugs with severe toxic side effects, as well as For example, Imatinib mesylate has been used in the treatment of hematologic diseases. For example, since its approval, imatinib mesylate has replaced interferon + hydroxyurea as the preferred treatment for chronic granulocytic leukemia in the U.S. It has high efficacy in the chronic phase of chronic granulocytes, and also has high efficacy in the accelerated and acute phases of chronic granulocytes, with few toxic side effects and better patient tolerance. The main disadvantage is that it is expensive and the discontinuation time is difficult to determine. In addition, the treatment of diffuse large B-cell non-Hodgkin’s lymphoma, acute B-lymphocytic leukemia and refractory thrombocytopenic purpura with melotrigine, and the treatment of senile acute myeloid leukemia with melotrigine are significantly better than conventional therapies. At present, the latest generation of hematological gene therapy drugs with more advantages have entered the clinical trial stage and are expected to be put into clinical treatment in the near future. Our extensive clinical practice shows that the use of microscopic gene targeting drugs in combination with macroscopic evidence-based treatment in Chinese medicine for these hematologic patients can add wings to the gene targeting drugs and complement each other, significantly improving their efficacy and reducing their side effects.